Targeting the Residual Leukemia Cells after Chemotherapy

Ly P Vu; Michael G Kharas

doi:10.1016/j.ccell.2018.08.012

Targeting the Residual Leukemia Cells after Chemotherapy

Cancer Cell. 2018 Sep 10;34(3):353-355. doi: 10.1016/j.ccell.2018.08.012.

Authors

Ly P Vu¹, Michael G Kharas²

Affiliations

¹ Molecular Pharmacology Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Molecular Pharmacology Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: kharasm@mskcc.org.

PMID: 30205040
DOI: 10.1016/j.ccell.2018.08.012

Abstract

One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML recurrence.

Publication types

Comment

MeSH terms

Antineoplastic Agents*
Humans
Leukemia, Myeloid, Acute*
Recurrence

Substances

Antineoplastic Agents